Shares Outstanding Shares Outstanding n/a Close	81.59M
Shares Change (YoY) Shares Change (YoY) n/a Close	27.67%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	2.87%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	99.99%
Shares Floating Shares Floating n/a Close	73.61M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	1,379
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.16%

Short Selling Information

The latest short interest is 10.7M, so 13.12% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	10.7M
Short % of Shares Out Short % of Shares Out n/a Close	13.12%
Short % of Float Short % of Float n/a Close	13.7%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	13.22

Valuation Ratios

The PE ratio is -4.82 and the forward PE ratio is -3.86. Viridian Therapeutics's PEG ratio is 0.19.

PE Ratio PE Ratio n/a Close	-4.82
Forward PE Forward PE n/a Close	-3.86
PS Ratio PS Ratio n/a Close	4309.18
Forward PS Forward PS n/a Close	1.2
PB Ratio PB Ratio n/a Close	1.94
P/FCF Ratio P/FCF Ratio n/a Close	-5.59
PEG Ratio PEG Ratio n/a Close	0.19

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Viridian Therapeutics.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 15.43, with a Debt / Equity ratio of 0.03.

Current Ratio Current Ratio n/a Close	15.43
Quick Ratio Quick Ratio n/a Close	15.43
Debt / Equity Debt / Equity n/a Close	0.03
Debt / EBITDA Debt / EBITDA n/a Close	-0.08
Debt / FCF Debt / FCF n/a Close	-0.09
Interest Coverage Interest Coverage n/a Close	-98.17

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$2,111.89
Profits Per Employee Profits Per Employee n/a Close	$-1,887,755.24
Employee Count Employee Count n/a Close	143
Asset Turnover Asset Turnover n/a Close	0
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by 15.05% in the last 52 weeks. The beta is 0.46, so Viridian Therapeutics's price volatility has been higher than the market average.

Beta Beta n/a Close	0.46
52-Week Price Change 52-Week Price Change n/a Close	15.05%
50-Day Moving Average 50-Day Moving Average n/a Close	13.75
200-Day Moving Average 200-Day Moving Average n/a Close	17.81
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	51.81
Average Volume (20 Days) Average Volume (20 Days) n/a Close	885,148

Income Statement

In the last 12 months, Viridian Therapeutics had revenue of 302K and earned -269.95M in profits. Earnings per share was -3.98.

Revenue Revenue n/a Close	302K
Gross Profit Gross Profit n/a Close	-938K
Operating Income Operating Income n/a Close	-299.04M
Net Income Net Income n/a Close	-269.95M
EBITDA EBITDA n/a Close	-265.66M
EBIT EBIT n/a Close	-266.9M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-3.98

Full Income Statement

Balance Sheet

The company has 99.59M in cash and 21.09M in debt, giving a net cash position of 78.5M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	99.59M
Total Debt Total Debt n/a Close	21.09M
Net Cash Net Cash n/a Close	78.5M
Retained Earnings Retained Earnings n/a Close	-995.86M
Total Assets Total Assets n/a Close	660.98M
Working Capital Working Capital n/a Close	623.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -232.32M and capital expenditures -511K, giving a free cash flow of -232.83M.

Operating Cash Flow Operating Cash Flow n/a Close	-232.32M
Capital Expenditures Capital Expenditures n/a Close	-511K
Free Cash Flow Free Cash Flow n/a Close	-232.83M
FCF Per Share FCF Per Share n/a Close	-3.43

Full Cash Flow Statement

Margins

Gross margin is -310.6%, with operating and profit margins of -99018.21% and -89387.09%.

Gross Margin Gross Margin n/a Close	-310.6%
Operating Margin Operating Margin n/a Close	-99018.21%
Pretax Margin Pretax Margin n/a Close	-89387.09%
Profit Margin Profit Margin n/a Close	-89387.09%
EBITDA Margin EBITDA Margin n/a Close	-87967.88%
EBIT Margin EBIT Margin n/a Close	-99018.21%
FCF Margin FCF Margin n/a Close	-77096.03%

Dividends & Yields

VRDN does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for VRDN is $36, which is 145.2% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$36
Price Target Difference Price Target Difference n/a Close	145.2%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	10

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Nov 13, 2020. It was a backward split with a ratio of 1:15.

Last Split Date Last Split Date n/a Close	Nov 13, 2020
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:15

Scores

Altman Z-Score Altman Z-Score n/a Close	9.42
Piotroski F-Score Piotroski F-Score n/a Close	2